ClinicalTrials.gg
Status unknownNCT02206165Updated Mar 30, 2015

A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

A Phase 2 interventional study of Candesartan 8mg and Candesartan 16mg in Essential Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-30.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Planned enrollment
8th of 34
456 · median 314
Started
2014
with 6 others
Phase 2
4 of 34
none open now
Registered
17th of 34
by date

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 8th largest by planned enrollment, is one of 7 that started in 2014, is one of 4 in phase 2, and was the 17th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Candesartan/Amlodipine combined or alone and select better dose of CKD-330 in essential hypertension patients.

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 or above
  • Essential hypertension with 90mmHg ≤ mean sitDBP ≤ 115mmHg on target arm at Visit 3
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • nean sitDBP ≥ 116mmHg or mean sitSBP ≥ 200mmHg at Visit 1, Visit 2, Visit 3
  • The change of mean sitDBP ≥ 10mmHg or mean sitSBP ≥ 20mmHg on target arm at Visit 1
  • Known or suspected Stage 2 Hypertension (aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
  • Patients with congestive heart failure( class III\~IV), ischemic heart disease, cardiomyopathy, heart valve disorder, arrhythmia, coronary artery bypass graft
  • History of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
  • Type I Diabets Mellitus, Type II Diabetes Mellitus with > 8%
  • History of severe or malignant retinopathy
  • /ALT > UNL * 2, Serum Creatinine > UNL * 1.5, K > 5.5mEq/L
  • Patients with acute or chronic inflammatory status, disease
  • Patients who need to take antihypertensive drug besides products
  • Patients must be treated with medications prohibited for concomitant use during study period
  • Hypersensitive to Candesartan/Amlodipine or other dihydropyridine drugs
  • Hereditary angioedema or history of angioedema related to ACE inhibitor or angiotensin II receptor blockers
  • History of malignant tumor within 5 years
  • Patients who are dependent on drugs or alcohol
  • History of disability to drug absorption, active inflammatory bowel syndrome with 12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract
  • Patients treated with other investigational product within 4 weeks at the time concents are obtained
  • Women with pregnant, breast-feeding
  • Not eligible to participate for study at the discretion of investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
456 participants (estimated)

Study arms

  • Experimental
    Candesartan 8mg + Amlodipine 5mg

    Candesartan 8mg + Amlodipine 5mg, po, q.d.

    Drug: Candesartan 8mg · Drug: Amlodipine 5mg

  • Experimental
    Candesartan 8mg + Amlodipine 10mg

    Candesartan 8mg + Amlodipine 10mg, po, q.d.

    Drug: Candesartan 8mg · Drug: Amlodipine 10mg

  • Experimental
    Candesartan 16mg + Amlodipine 5mg

    Candesartan 16mg + Amlodipine 5mg, po, q.d.

    Drug: Candesartan 16mg · Drug: Amlodipine 5mg

  • Experimental
    Candesartan 16mg + Amlodipine 10mg

    Candesartan 16mg + Amlodipine 10mg, po, q.d.

    Drug: Candesartan 16mg · Drug: Amlodipine 10mg

  • Active comparator
    Candesartan 8mg

    Candesartan 8mg, po, q.d.

    Drug: Candesartan 8mg

  • Active comparator
    Candesartan 16mg

    Candesartan 16mg, po, q.d.

    Drug: Candesartan 16mg

  • Active comparator
    Amlodipine 5mg

    Amlodipine 5mg, po, q.d.

    Drug: Amlodipine 5mg

  • Active comparator
    Amlodipine 10mg

    Amlodipine 10mg, po, q.d.

    Drug: Amlodipine 10mg

Interventions

06

What researchers measure

Primary outcomes

  1. The mean change of sitDBP (sitting diastolic blood pressure)

    Time frame: From baseline at week 8

Secondary outcomes

  1. The mean change of sitDBP

    Time frame: From baseline at week 4 and week 8

  2. The mean change of sitSBP

    Time frame: From baseline at week 4 and 8

  3. Responder rate: The change of sitDBP > 10mmHg, sitSBP > 20mmHg

    Time frame: From baseline at week 4 and 8

  4. Control rate: Patient achieving sitDBP < 90mmHg and sitSBP < 140mmHg

    Time frame: At week 4 and 8

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Bundang Hospital
    Seongnam, Korea, Republic of
    Recruiting
    • Cheol-Ho Kim, M.D., Ph.D. · Contact
    • Cheol-Ho Kim, M.D., Ph.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Apr 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2014
First posted
Aug 1, 2014
Start
Mar 2014
Primary completionEst.
Apr 2015
CompletionEst.
Jun 2015
Last update
Mar 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02206165
Responsible party
Sponsor
First posted
Aug 1, 2014
Start date
Mar 2014
Primary completion
Apr 2015 (estimated)
Completion
Jun 2015 (estimated)
Last update
Mar 30, 2015

Study contacts

HyunKyung Oh
Contact
hkoh@ckdpharm.com
82-2-2194-0469
Cheol-Ho Kim, M.D., Ph.D.
principal investigator · Seoul National University Bundang Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Candesartan · Amlodipine

Start the discussion